Skip to main content
NORTHEAST PHARMACEUTICAL GROUP CO.,LTD logo

NORTHEAST PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 000597 ISIN · CNE0000009G0 LEI · 300300HX6JTMOEENF158 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,606 across all filing types
Latest filing 2022-05-31 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000597

About NORTHEAST PHARMACEUTICAL GROUP CO.,LTD

https://www.nepharm.com.cn

Northeast Pharmaceutical Group Co., Ltd. (NEPG) specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs) and finished dosage forms. The company operates as a large-scale integrated pharmaceutical enterprise with a diverse product portfolio encompassing vitamins, antibiotics, cardiovascular agents, and digestive system medications. NEPG is recognized as a global leader in the production of Vitamin C and Vitamin B1, alongside significant output in caffeine and fosfomycin. Its manufacturing facilities adhere to international quality standards, including Good Manufacturing Practice (GMP) certifications. The company serves a broad international market, exporting products to numerous countries while maintaining a strong domestic presence. NEPG focuses on technological innovation and industrial scaling to provide high-quality chemical raw materials and pharmaceutical preparations for global healthcare needs.

Recent filings

Filing Released Lang Actions
关于2022年限制性股票激励计划内幕信息知情人及激励对象买卖公司股票情况的自查报告
Regulatory Filings Classification · 95% confidence The document is a self-inspection report regarding insider trading related to a 2022 restricted stock incentive plan. It details the investigation of insider information holders and their stock trading activities, confirming no insider trading occurred. The document is a regulatory announcement about compliance and insider trading checks, not a financial report, earnings release, or management report. It does not contain financial statements or detailed financial data. It fits best under Regulatory Filings (RNS) as it is a compliance-related disclosure about insider trading and stock incentive plans.
2022-05-31 Chinese
关于公司董事长、高级管理人员增持公司股份期满及部分人员延长增持期的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the completion and extension of a share purchase plan by the company's chairman and senior management. It details the number of shares purchased, the amounts involved, and compliance with regulatory requirements. It does not contain financial statements or performance data but reports on insider share transactions by directors and executives. This fits the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 2668 characters, which is typical for such announcements. Therefore, the appropriate classification is DIRS.
2022-05-29 Chinese
关于控股子公司被申请清算的进展公告
Legal Proceedings Report Classification · 95% confidence The document is an announcement regarding the progress of a liquidation case involving a controlling subsidiary of the company. It details legal proceedings, court decisions, and potential impacts on the company. The document is relatively short (2987 characters) and focuses on legal updates rather than financial statements or detailed financial data. It does not contain financial results, management discussion, or audit information. The content fits the description of a Legal Proceedings Report, which covers updates on significant lawsuits or regulatory actions involving the company.
2022-05-26 Chinese
关于召开公司2022年第一次临时股东大会的提示性公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed announcement about the convening of the company's 2022 first extraordinary general meeting of shareholders (临时股东大会). It includes information about the meeting date, voting procedures, proposals to be voted on, and instructions for shareholders. It does not contain financial statements or results but is a notice related to a shareholder meeting. The document length is 3881 characters, which is relatively short and primarily serves as a meeting notice and voting instructions. This fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2022-05-26 Chinese
监事会关于公司2022年限制性股票激励计划首次授予激励对象名单的审核及公示情况说明
Capital/Financing Update Classification · 95% confidence The document is a public announcement by the supervisory board regarding the review and public disclosure of the initial grant list of restricted stock incentive plan participants for the year 2022. It discusses compliance with relevant laws and internal company regulations, and confirms the legitimacy and qualifications of the incentive recipients. The document is short (1220 characters) and does not contain financial statements or detailed financial data. It is an announcement related to a capital incentive plan, specifically about the approval and public notice of the stock incentive grant list. This fits best under the category of Capital/Financing Update (CAP), as it relates to stock incentive plans and equity-based compensation updates rather than a full report or regulatory filing.
2022-05-25 Chinese
2021年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is titled as an announcement regarding the implementation of the 2021 annual equity distribution (dividend) plan by Dongbei Pharmaceutical Group Co., Ltd. It details the dividend amount, the approval date by the shareholders' meeting, the record date, and the payment method. The document is relatively short (1788 characters) and focuses on the dividend distribution details rather than providing a full financial report or comprehensive analysis. It does not contain full financial statements or management discussion but is an official announcement of dividend payment details following shareholder approval. Therefore, it fits the category of a Notice of Dividend Amount (DIV).
2022-05-19 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.